Using RNA-loaded nanoparticles to fight metastatic osteosarcoma
Overcoming metastatic spread of osteosarcoma with RNA loaded nanoparticles
This study is testing a new type of vaccine made from RNA and tiny particles to help boost the immune system's ability to fight osteosarcoma, especially when it has spread to the lungs, and it's aimed at improving treatment options for patients with this type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project ID | NIH-10914813 on NIH RePORTER |
What this research studies
This research focuses on developing a novel RNA-nanoparticle vaccine designed to enhance the immune response against osteosarcoma, particularly in cases where the cancer has spread to the lungs. By utilizing a unique engineering approach, the vaccine aims to penetrate and reprogram the tumor microenvironment while stimulating both innate and adaptive immune responses. The goal is to activate the immune system quickly and effectively, leading to improved anti-tumor efficacy and long-term survival benefits in patients with metastatic osteosarcoma. The study involves testing the safety and effectiveness of this innovative treatment in preclinical models before potential application in human patients.
Who could benefit from this research
Good fit: Ideal candidates for this research include children and adolescents diagnosed with osteosarcoma, particularly those with metastatic disease.
Not a fit: Patients with osteosarcoma that is localized and has not metastasized may not benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective immunotherapy option for patients with metastatic osteosarcoma, potentially improving survival rates.
How similar studies have performed: Previous research has shown promise in using RNA-nanoparticle technologies for cancer treatment, indicating potential for success in this novel approach.
Where this research is happening
Gainesville, United States
- University of Florida — Gainesville, United States (Active)
Researchers
- Principal investigator: Sayour, Elias — University of Florida
- Study coordinator: Sayour, Elias
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.